SCOPUS 정보 검색 플랫폼

Volumn 125, Issue 1, 2011, Pages 279-287

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

(18) Thompson, Alastair M a,b Johnson, Andrea c Quinlan, Philip a Hillman, Grantland c Fontecha, Marcel c Bray, Susan E a Purdie, Colin A a Jordan, Lee B a Ferraldeschi, Roberta d,e Latif, Ayshe d Hadfield, Kirsten D d Clarke, Robert B f Ashcroft, Linda e Evans, D Gareth d Howell, Anthony e Nikoloff, Michele c Lawrence, Jeffrey c Newman, William G d

a UNIVERSITY OF DUNDEE (United Kingdom)

b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (United States)

c Roche Molecular Diagnostics (United States)

d UNIVERSITY OF MANCHESTER (United Kingdom)

e CHRISTIE HOSPITAL (United Kingdom)

f UNIVERSITY OF MANCHESTER (United Kingdom)

Author keywords

Adherence; CYP2D6; Cytochrome P450; Pharmacogenetics; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 2D6; TAMOXIFEN;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONOTHERAPY; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME; UNITED KINGDOM;

AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MEDICATION ADHERENCE; MIDDLE AGED; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 78651076124 PISSN: 01676806 EISSN: 15737217 Source Type: Journal
DOI: 10.1007/s10549-010-1139-x Document Type: Article

Times cited : (84)

References (31)

1
- 60749122030
- Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer
- 10.1186/bcr2177 19128430
- JN Ingle 2008 Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer Breast Cancer Res 10 Suppl 4 S17 10.1186/bcr2177 19128430
- (2008) Breast Cancer Res , vol.10 , Issue.SUPPL. 4 , pp. 17
- Ingle, J.N.¹

2
- 3342932419
- Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
- DOI 10.1023/B:BREA.0000025406.31193.e8
- MD Johnson H Zuo KH Lee JP Trebley JM Rae RV Weatherman Z Desta DA Flockhart TC Skaar 2004 Pharmacological characterization of 4-hydroxy-N- desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat 85 151 159 1:CAS:528:DC%2BD2cXjsVertbc%3D 10.1023/B:BREA.0000025406.31193. e8 15111773 (Pubitemid 38987269)
- (2004) Breast Cancer Research and Treatment , vol.85 , Issue.2 , pp. 151-159
- Johnson, M.D.¹ Zuo, H.² Lee, K.-H.³ Trebley, J.P.⁴ Rae, J.M.⁵ Weatherman, R.V.⁶ Desta, Z.⁷ Flockhart, D.A.⁸ Skaar, T.C.⁹

3
- 0032569831
- Tamoxifen in the treatment of breast cancer
- DOI 10.1056/NEJM199811263392207
- CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618 1:CAS:528:DyaK1cXnvFOitLs%3D 10.1056/NEJM199811263392207 9828250 (Pubitemid 28536137)
- (1998) New England Journal of Medicine , vol.339 , Issue.22 , pp. 1609-1618
- Osborne, C.K.¹

4
- 0031038038
- Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
- 1:CAS:528:DyaK2sXhtVCju74%3D 9012401
- C Sachse J Brockmoller S Bauer I Roots 1997 Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 284 295 1:CAS:528:DyaK2sXhtVCju74%3D 9012401
- (1997) Am J Hum Genet , vol.60 , pp. 284-295
- Sachse, C.¹ Brockmoller, J.² Bauer, S.³ Roots, I.⁴

5
- 58849087666
- Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer
- 1:CAS:528:DC%2BD1MXhs1elug%3D%3D 10.1158/1078-0432.CCR-08-2006 19118028
- VO Dezentje HJ Guchelaar JW Nortier CJ van de Velde H Gelderblom 2009 Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer Clin Cancer Res 15 15 21 1:CAS:528:DC%2BD1MXhs1elug%3D%3D 10.1158/1078-0432.CCR-08-2006 19118028
- (2009) Clin Cancer Res , vol.15 , pp. 15-21
- Dezentje, V.O.¹ Guchelaar, H.J.² Nortier, J.W.³ Van De Velde, C.J.⁴ Gelderblom, H.⁵

6
- 56749152357
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
- 1:CAS:528:DC%2BD1cXhsVajtbrL 10.1038/sj.bjc.6604758 18985046
- C McCowan J Shearer PT Donnan JA Dewar M Crilly AM Thompson TP Fahey 2008 Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 99 1763 1768 1:CAS:528:DC%2BD1cXhsVajtbrL 10.1038/sj.bjc.6604758 18985046
- (2008) Br J Cancer , vol.99 , pp. 1763-1768
- McCowan, C.¹ Shearer, J.² Donnan, P.T.³ Dewar, J.A.⁴ Crilly, M.⁵ Thompson, A.M.⁶ Fahey, T.P.⁷

7
- 0346602691
- Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
- 1:CAS:528:DC%2BD3sXpvVelsbc%3D 14652237
- V Stearns MD Johnson JM Rae A Morocho A Novielli P Bhargava DF Hayes Z Desta DA Flockhart 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758 1764 1:CAS:528:DC%2BD3sXpvVelsbc%3D 14652237
- (2003) J Natl Cancer Inst , vol.95 , pp. 1758-1764
- Stearns, V.¹ Johnson, M.D.² Rae, J.M.³ Morocho, A.⁴ Novielli, A.⁵ Bhargava, P.⁶ Hayes, D.F.⁷ Desta, Z.⁸ Flockhart, D.A.⁹

8
- 59449093708
- A candidate signature associated with tamoxifen failure in primary breast cancer
- 10.1186/bcr2158 18928543
- J Vendrell KE Robertson P Ravel SE Bray A Bajard CA Purdie C Nguyen SM Hadad I Bieche S Chabaud T Bachelot AM Thompson PA Cohen 2008 A candidate signature associated with tamoxifen failure in primary breast cancer Breast Cancer Res 10 R88 10.1186/bcr2158 18928543
- (2008) Breast Cancer Res , vol.10 , pp. 88
- Vendrell, J.¹ Robertson, K.E.² Ravel, P.³ Bray, S.E.⁴ Bajard, A.⁵ Purdie, C.A.⁶ Nguyen, C.⁷ Hadad, S.M.⁸ Bieche, I.⁹ Chabaud, S.¹⁰ Bachelot, T.¹¹ Thompson, A.M.¹² Cohen, P.A.¹³

9
- 33644639136
- Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
- 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D 10.1200/JCO.2005.03.3266 16361630
- MP Goetz JM Rae VJ Suman SL Safgren MM Ames DW Visscher C Reynolds FJ Couch WL Lingle DA Flockhart Z Desta EA Perez JN Ingle 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9318 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D 10.1200/JCO.2005.03.3266 16361630
- (2005) J Clin Oncol , vol.23 , pp. 9312-9318
- Goetz, M.P.¹ Rae, J.M.² Suman, V.J.³ Safgren, S.L.⁴ Ames, M.M.⁵ Visscher, D.W.⁶ Reynolds, C.⁷ Couch, F.J.⁸ Lingle, W.L.⁹ Flockhart, D.A.¹⁰ Desta, Z.¹¹ Perez, E.A.¹² Ingle, J.N.¹³

10
- 36349024762
- Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
- DOI 10.1200/JCO.2007.12.2705
- W Schroth L Antoniadou P Fritz M Schwab T Muerdter UM Zanger W Simon M Eichelbaum H Brauch 2007 Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 5187 5193 1:CAS:528:DC%2BD2sXhsVKnsbzN 10.1200/JCO.2007.12.2705 18024866 (Pubitemid 350232249)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.33 , pp. 5187-5193
- Schroth, W.¹ Antoniadou, L.² Fritz, P.³ Schwab, M.⁴ Muerdter, T.⁵ Zanger, U.M.⁶ Simon, W.⁷ Eichelbaum, M.⁸ Brauch, H.⁹

11
- 70349929431
- Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
- 1:CAS:528:DC%2BD1MXht1CksrjO 10.1001/jama.2009.1420 19809024
- W Schroth MP Goetz U Hamann PA Fasching M Schmidt S Winter P Fritz W Simon VJ Suman MM Ames SL Safgren MJ Kuffel HU Ulmer J Boländer R Strick MW Beckmann H Koelbl RM Weinshilboum JN Ingle M Eichelbaum M Schwab H Brauch 2009 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen JAMA 302 1429 1436 1:CAS:528:DC%2BD1MXht1CksrjO 10.1001/jama.2009.1420 19809024
- (2009) JAMA , vol.302 , pp. 1429-1436
- Schroth, W.¹ Goetz, M.P.² Hamann, U.³ Fasching, P.A.⁴ Schmidt, M.⁵ Winter, S.⁶ Fritz, P.⁷ Simon, W.⁸ Suman, V.J.⁹ Ames, M.M.¹⁰ Safgren, S.L.¹¹ Kuffel, M.J.¹² Ulmer, H.U.¹³ Boländer, J.¹⁴ Strick, R.¹⁵ Beckmann, M.W.¹⁶ Koelbl, H.¹⁷ Weinshilboum, R.M.¹⁸ Ingle, J.N.¹⁹ Eichelbaum, M.²⁰ Schwab, M.²¹ Brauch, H.²² more..

12
- 72449150287
- Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
- 10.1007/s10549-009-0328-y 19189210
- T Ramón y Cajal A Altés L Paré E del Rio C Alonso A Barnadas M Baiget 2010 Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment Breast Cancer Res Treat 119 33 38 10.1007/s10549-009- 0328-y 19189210
- (2010) Breast Cancer Res Treat , vol.119 , pp. 33-38
- Ramón Y Cajal, T.¹ Altés, A.² Paré, L.³ Del Rio, E.⁴ Alonso, C.⁵ Barnadas, A.⁶ Baiget, M.⁷

13
- 77950502100
- Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients
- 1:CAS:528:DC%2BC3cXksFSqtb0%3D 10.1200/JCO.2009.25.7246 20124171
- K Kiyotani T Mushiroda CK Imamura N Hosono T Tsunoda M Kubo Y Tanigawara DA Flockhart Z Desta TC Skaar F Aki K Hirata Y Takatsuka M Okazaki S Ohsumi T Yamakawa M Sasa Y Nakamura H Zembutsu 2010 Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients J Clin Oncol 28 1287 1293 1:CAS:528:DC%2BC3cXksFSqtb0%3D 10.1200/JCO.2009.25.7246 20124171
- (2010) J Clin Oncol , vol.28 , pp. 1287-1293
- Kiyotani, K.¹ Mushiroda, T.² Imamura, C.K.³ Hosono, N.⁴ Tsunoda, T.⁵ Kubo, M.⁶ Tanigawara, Y.⁷ Flockhart, D.A.⁸ Desta, Z.⁹ Skaar, T.C.¹⁰ Aki, F.¹¹ Hirata, K.¹² Takatsuka, Y.¹³ Okazaki, M.¹⁴ Ohsumi, S.¹⁵ Yamakawa, T.¹⁶ Sasa, M.¹⁷ Nakamura, Y.¹⁸ Zembutsu, H.¹⁹

14
- 21344467511
- Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
- DOI 10.1007/s10549-004-7751-x
- SA Nowell J Ahn JM Rae JO Scheys A Trovato C Sweeney SL MacLeod FF Kadlubar CB Ambrosone 2005 Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 249 258 1:CAS:528:DC%2BD2MXltFGqsLs%3D 10.1007/s10549-004-7751-x 15952058 (Pubitemid 40903087)
- (2005) Breast Cancer Research and Treatment , vol.91 , Issue.3 , pp. 249-258
- Nowell, S.A.¹ Ahn, J.² Rae, J.M.³ Scheys, J.O.⁴ Trovato, A.⁵ Sweeney, C.⁶ MacLeod, S.L.⁷ Kadlubar, F.F.⁸ Ambrosone, C.B.⁹

15
- 29144491089
- Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
- 1:CAS:528:DC%2BD2MXitF2qtr0%3D 10.1186/bcr993 15987423
- P Wegman L Vainikka O Stål B Nordenskjöld L Skoog LE Rutqvist S Wingren 2005 Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 R284 R290 1:CAS:528:DC%2BD2MXitF2qtr0%3D 10.1186/bcr993 15987423
- (2005) Breast Cancer Res , vol.7
- Wegman, P.¹ Vainikka, L.² Stål, O.³ Nordenskjöld, B.⁴ Skoog, L.⁵ Rutqvist, L.E.⁶ Wingren, S.⁷

16
- 34248208754
- Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
- DOI 10.1186/bcr1640
- P Wegman S Elingarami J Carstensen O Stål B Nordenskjold S Wingren 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 R7 10.1186/bcr1640 17244352 (Pubitemid 350215154)
- (2007) Breast Cancer Research , vol.9 , Issue.1
- Wegman, P.¹ Elingarami, S.² Carstensen, J.³ Stal, O.⁴ Nordenskjold, B.⁵ Wingren, S.⁶

17
- 67651177578
- Genotype-guided tamoxifen therapy: Time to pause for reflection?
- 1:CAS:528:DC%2BD1MXptlals7s%3D 10.1016/S1470-2045(09)70030-0 19647203
- TL Lash EA Lien HT Sørensen S Hamilton-Dutoit 2009 Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10 825 833 1:CAS:528:DC%2BD1MXptlals7s%3D 10.1016/S1470-2045(09)70030-0 19647203
- (2009) Lancet Oncol , vol.10 , pp. 825-833
- Lash, T.L.¹ Lien, E.A.² Sørensen, H.T.³ Hamilton-Dutoit, S.⁴

18
- 60749093747
- Pharmacogenetics of tamoxifen: Who should undergo CYP2D6 genetic testing?
- 1:CAS:528:DC%2BD1MXjs1Oktbk%3D
- MJ Higgins JM Rae DA Flockhart DF Hayes V Stearns 2009 Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Cancer Netw 7 203 213 1:CAS:528:DC%2BD1MXjs1Oktbk%3D
- (2009) J Natl Compr Cancer Netw , vol.7 , pp. 203-213
- Higgins, M.J.¹ Rae, J.M.² Flockhart, D.A.³ Hayes, D.F.⁴ Stearns, V.⁵

19
- 67749114265
- CYP2D6 and tamoxifen: DNA matters in breast cancer
- 1:CAS:528:DC%2BD1MXovFylt78%3D 10.1038/nrc2683 19629072
- JM Hoskins LA Carey HL McLeod 2009 CYP2D6 and tamoxifen: DNA matters in breast cancer Nat Rev Cancer 9 576 586 1:CAS:528:DC%2BD1MXovFylt78%3D 10.1038/nrc2683 19629072
- (2009) Nat Rev Cancer , vol.9 , pp. 576-586
- Hoskins, J.M.¹ Carey, L.A.² McLeod, H.L.³

20
- 67849116739
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
- COBRA investigators. 1:CAS:528:DC%2BD1MXlsVKksbw%3D 10.1038/tpj.2009.14 19421167
- JM Rae MJ Sikora NL Henry L Li S Kim S Oesterreich TC Skaar AT Nguyen Z Desta AM Storniolo DA Flockhart DF Hayes V Stearns COBRA investigators 2009 Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients Pharmacogenomics J 9 258 264 1:CAS:528: DC%2BD1MXlsVKksbw%3D 10.1038/tpj.2009.14 19421167
- (2009) Pharmacogenomics J , vol.9 , pp. 258-264
- Rae, J.M.¹ Sikora, M.J.² Henry, N.L.³ Li, L.⁴ Kim, S.⁵ Oesterreich, S.⁶ Skaar, T.C.⁷ Nguyen, A.T.⁸ Desta, Z.⁹ Storniolo, A.M.¹⁰ Flockhart, D.A.¹¹ Hayes, D.F.¹² Stearns, V.¹³

21
- 19944434201
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
- 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 10.1093/jnci/dji005 15632378
- Y Jin Z Desta V Stearns B Ward H Ho KH Lee T Skaar AM Storniolo L Li A Araba R Blanchard A Nguyen L Ullmer J Hayden S Lemler RM Weinshilboum JM Rae DF Hayes DA Flockhart 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 10.1093/jnci/dji005 15632378
- (2005) J Natl Cancer Inst , vol.97 , pp. 30-39
- Jin, Y.¹ Desta, Z.² Stearns, V.³ Ward, B.⁴ Ho, H.⁵ Lee, K.H.⁶ Skaar, T.⁷ Storniolo, A.M.⁸ Li, L.⁹ Araba, A.¹⁰ Blanchard, R.¹¹ Nguyen, A.¹² Ullmer, L.¹³ Hayden, J.¹⁴ Lemler, S.¹⁵ Weinshilboum, R.M.¹⁶ Rae, J.M.¹⁷ Hayes, D.F.¹⁸ Flockhart, D.A.¹⁹

22
- 33847034287
- The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
- DOI 10.1007/s10549-006-9428-0
- MP Goetz SK Knox VJ Suman JM Rae SL Safgren MM Ames DW Visscher C Reynolds FJ Couch WL Lingle RM Weinshilboum EG Fritcher AM Nibbe Z Desta A Nguyen DA Flockhart EA Perez JN Ingle 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 113 121 1:CAS:528:DC%2BD2sXisVylsg%3D%3D 10.1007/s10549-006-9428-0 17115111 (Pubitemid 47555336)
- (2007) Breast Cancer Research and Treatment , vol.101 , Issue.1 , pp. 113-121
- Goetz, M.P.¹ Knox, S.K.² Suman, V.J.³ Rae, J.M.⁴ Safgren, S.L.⁵ Ames, M.M.⁶ Visscher, D.W.⁷ Reynolds, C.⁸ Couch, F.J.⁹ Lingle, W.L.¹⁰ Weinshilboum, R.M.¹¹ Fritcher, E.G.B.¹² Nibbe, A.M.¹³ Desta, Z.¹⁴ Nguyen, A.¹⁵ Flockhart, D.A.¹⁶ Perez, E.A.¹⁷ Ingle, J.N.¹⁸

23
- 53249086540
- Impaired tamoxifen metabolism reduces survival in familial breast cancer patients
- 1:CAS:528:DC%2BD1cXhtFaitrjF 10.1158/1078-0432.CCR-07-5235 18794105
- WG Newman KD Hadfield A Latif SA Roberts A Shenton C McHague F Lalloo S Howell DG Evans 2008 Impaired tamoxifen metabolism reduces survival in familial breast cancer patients Clin Cancer Res 14 5913 5938 1:CAS:528:DC%2BD1cXhtFaitrjF 10.1158/1078-0432.CCR-07-5235 18794105
- (2008) Clin Cancer Res , vol.14 , pp. 5913-5938
- Newman, W.G.¹ Hadfield, K.D.² Latif, A.³ Roberts, S.A.⁴ Shenton, A.⁵ McHague, C.⁶ Lalloo, F.⁷ Howell, S.⁸ Evans, D.G.⁹

24
- 70349328422
- No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications
- 1:CAS:528:DC%2BD1MXhtFWltb7N 10.1158/1055-9965.EPI-09-0516 19690182
- TP Ahern L Pedersen DP Cronin-Fenton HT Sørensen TL Lash 2009 No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications Cancer Epidemiol Biomarkers Prev 18 2562 2564 1:CAS:528:DC%2BD1MXhtFWltb7N 10.1158/1055-9965.EPI-09-0516 19690182
- (2009) Cancer Epidemiol Biomarkers Prev , vol.18 , pp. 2562-2564
- Ahern, T.P.¹ Pedersen, L.² Cronin-Fenton, D.P.³ Sørensen, H.T.⁴ Lash, T.L.⁵

25
- 76649089656
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study
- 10.1136/bmj.c693 20142325
- CM Kelly DN Juurlink T Gomes M Duong-Hua KI Pritchard PC Austin LF Paszat 2010 Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ 340 c693 10.1136/bmj.c693 20142325
- (2010) BMJ , vol.340 , pp. 693
- Kelly, C.M.¹ Juurlink, D.N.² Gomes, T.³ Duong-Hua, M.⁴ Pritchard, K.I.⁵ Austin, P.C.⁶ Paszat, L.F.⁷

26
- 77952521444
- Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer
- 10.1200/JCO.2009.25.0894 20385997
- VO Dezentjé NJ van Blijderveen H Gelderblom H Putter MP van Herk-Sukel MK Casparie AC Egberts JW Nortier HJ Guchelaar 2010 Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer J Clin Oncol 28 2423 2429 10.1200/JCO.2009.25.0894 20385997
- (2010) J Clin Oncol , vol.28 , pp. 2423-2429
- Dezentjé, V.O.¹ Van Blijderveen, N.J.² Gelderblom, H.³ Putter, H.⁴ Van Herk-Sukel, M.P.⁵ Casparie, M.K.⁶ Egberts, A.C.⁷ Nortier, J.W.⁸ Guchelaar, H.J.⁹

27
- 77956242845
- CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification
- Epub ahead of print
- Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, Schwab M, Brauch HB (2010) CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res Jun 1. [Epub ahead of print]
- (2010) Clin Cancer Res Jun 1
- Schroth, W.¹ Hamann, U.² Fasching, P.A.³ Dauser, S.⁴ Winter, S.⁵ Eichelbaum, M.⁶ Schwab, M.⁷ Brauch, H.B.⁸

28
- 70349910091
- The CYP2D6 4 polymorphism affects breast cancer survival in tamoxifen users
- 1:CAS:528:DC%2BD1MXht1GmtbbI 10.1007/s10549-008-0272-2 19189212
- MJ Bijl RH van Schaik LA Lammers A Hofman AG Vulto T van Gelder BH Stricker LE Visser 2009 The CYP2D6 4 polymorphism affects breast cancer survival in tamoxifen users Breast Cancer Res Treat 118 125 130 1:CAS:528: DC%2BD1MXht1GmtbbI 10.1007/s10549-008-0272-2 19189212
- (2009) Breast Cancer Res Treat , vol.118 , pp. 125-130
- Bijl, M.J.¹ Van Schaik, R.H.² Lammers, L.A.³ Hofman, A.⁴ Vulto, A.G.⁵ Van Gelder, T.⁶ Stricker, B.H.⁷ Visser, L.E.⁸

29
- 0037441639
- Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
- DOI 10.1200/JCO.2003.07.071
- AH Partridge PS Wang EP Winer J Avorn 2003 Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer J Clin Oncol 21 602 606 1:CAS:528:DC%2BD2cXpsVGrtbs%3D 10.1200/JCO.2003.07.071 12586795 (Pubitemid 46621892)
- (2003) Journal of Clinical Oncology , vol.21 , Issue.4 , pp. 602-606
- Partridge, A.H.¹ Wang, P.S.² Winer, E.P.³ Avorn, J.⁴

30
- 61649109019
- Adherence with adjuvant hormonal therapy for breast cancer
- 1:STN:280:DC%2BD1M7ntVKhsw%3D%3D 10.1093/annonc/mdp039 19246419
- KJ Ruddy AH Partridge 2009 Adherence with adjuvant hormonal therapy for breast cancer Ann Oncol 20 401 402 1:STN:280:DC%2BD1M7ntVKhsw%3D%3D 10.1093/annonc/mdp039 19246419
- (2009) Ann Oncol , vol.20 , pp. 401-402
- Ruddy, K.J.¹ Partridge, A.H.²

31
- 33745347897
- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment
- DOI 10.1016/j.clpt.2006.03.013, PII S0009923606001366
- S Borges Z Desta L Li TC Skaar BA Ward A Nguyen Y Jin AM Storniolo DM Nikoloff L Wu G Hillman DF Hayes V Stearns DA Flockhart 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74 1:CAS:528:DC%2BD28Xms1enu7k%3D 10.1016/j.clpt.2006.03.013 16815318 (Pubitemid 43946844)
- (2006) Clinical Pharmacology and Therapeutics , vol.80 , Issue.1 , pp. 61-74
- Borges, S.¹ Desta, Z.² Li, L.³ Skaar, T.C.⁴ Ward, B.A.⁵ Nguyen, A.⁶ Jin, Y.⁷ Storniolo, A.M.⁸ Nikoloff, D.M.⁹ Wu, L.¹⁰ Hillman, G.¹¹ Hayes, D.F.¹² Stearns, V.¹³ Flockhart, D.A.¹⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.